Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • redhot47fla redhot47fla Nov 7, 2013 9:19 AM Flag

    ASH Abstract - Adcetris in frontline multi-agent non-Hodgkins - "substantial anti-tumor activity"

    Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas:

    All 26 pts were assessed for a clinical response at the end of treatment with A+CHP. The ORR was 100%, with a CR rate of 88%. All 7 non-ALCL pts achieved a CR. After a median observation time of 16 months, the 1-year PFS rate was 71% (95% CI 49, 85).

    Conclusions

    At a dose of 1.8 mg/kg, brentuximab vedotin, administered sequentially with CHOP or in combination with CHP, exhibited manageable toxicity in the treatment of newly-diagnosed CD30+ mature T/NK-cell lymphomas. A+CHP exhibited substantial antitumor activity, with an ORR of 100% (CR rate 88%) and a 1-year PFS rate of 71%. A phase 3 study comparing A+CHP to CHOP in the frontline treatment of mature T-cell lymphomas is underway (ClinicalTrials.gov NCT01777152).

 
SGEN
41.31+0.90(+2.23%)Jul 1 4:00 PMEDT